Full-Time

Staff Commodity Manager

Strategic Sourcing

Element Biosciences

Element Biosciences

201-500 employees

Low-cost next-generation DNA sequencing technology

Compensation Overview

$119k - $156k/yr

+ Stock options + Discretionary annual bonus + 401(k) company match

San Diego, CA, USA

Remote

Daily on-site work is required; domestic travel up to 10% for supplier visits.

Bachelor's

Category
Operations & Logistics (1)
Required Skills
NetSuite
CAD
Supply Chain Management
Data Visualization
GMP
SAP Products
Oracle
Excel/Numbers/Sheets

Get referred to Element Biosciences

See people who can refer or advise you

Requirements
  • Bachelor's degree in Engineering, Materials Science, or a related technical field.
  • 15+ years of progressive experience in strategic sourcing, procurement engineering, supplier quality, or associated supply chain roles, with experience in regulated industries.
  • Demonstrated expertise in commodity management and strategic sourcing across diverse materials and components, including high-complexity mechanical assemblies, electronics, and hardware.
  • Extensive experience negotiating complex commercial contracts, managing technical supplier relationships, and driving supplier performance improvements.
  • Ability to interpret engineering drawings, CAD models, technical specifications, and design documentation across mechanical and electrical systems.
  • Deep expertise in cost modeling, should-cost analysis, total-landed-cost calculation, and cost of goods sold management across product lifecycles.
  • Proven ability to lead strategic sourcing initiatives, supplier development programs, and supply chain transformation projects.
  • Proficiency with enterprise resource planning systems such as NetSuite, SAP, or Oracle, and advanced analytical tools such as Microsoft Excel, PowerPoint, and data visualization platforms.
  • Demonstrated ability to influence cross-functional teams and senior leadership on sourcing strategy, technical decisions, and risk management.
  • Ability to communicate, present, and manage stakeholders while challenging assumptions and providing objective, data-driven recommendations.
  • Ability to operate as a self-directed, analytically rigorous problem-solver with initiative and proactivity in driving continuous improvement and operational excellence.
  • Ability to frequently move boxes weighing up to 20 pounds.
Responsibilities
  • Develop and execute multi-year strategic sourcing roadmaps for assigned commodity families, aligning sourcing strategies with product development timelines, technology roadmaps, and cost of goods sold targets.
  • Define and implement sourcing governance frameworks for New Product Introduction and sustaining programs, including decision rights, stakeholder alignment, and risk management processes.
  • Lead supplier selection, qualification, and onboarding activities for direct materials, contract manufacturing partners, and technical services across the product lifecycle.
  • Influence design-for-cost and design-for-manufacturability early in the research and development cycle; collaborate with Engineering and R&D to drive make-versus-buy decisions and multi-sourcing strategies.
  • Evaluate suppliers for technical capability, manufacturability, cost efficiency, and readiness across New Product Introduction phases; act as the primary technical liaison between internal stakeholders and supplier engineering teams.
  • Conduct detailed cost breakdowns and total-landed-cost modeling using should-cost analysis; drive cost of goods sold optimization and cost avoidance initiatives across commodity families.
  • Develop and maintain supplier scorecards; lead Quarterly Business Reviews and corrective action planning; track and report sourcing key performance indicators for cost, quality, delivery, and supply chain resilience to leadership.
  • Strengthen supply chain resilience and continuity by qualifying alternate sources, implementing diversification strategies, and managing geopolitical and tariff-related risks.
  • Lead contract negotiations covering pricing, payment terms, risk-sharing, flexibility clauses, and supply continuity commitments; draft sourcing governance documents.
  • Interpret and leverage technical documentation, including engineering drawings, CAD models, and specifications, to ensure supplier understanding of requirements, manufacturability, and cost accuracy.
  • Partner with Quality and Regulatory to ensure supplier compliance with ISO 13485, RoHS, REACH, and GMP; support supplier quality audits and certification processes.
  • Represent Strategic Sourcing in cross-functional forums, including product roadmap syncs, design reviews, operations planning, and business reviews with executive leadership.
  • Maintain accurate sourcing documentation, Bill of Materials alignment, supplier records, and master data to ensure data integrity and compliance.
  • Deliver clear, data-driven presentations and updates to stakeholders on sourcing strategy, supplier performance, cost initiatives, and risk mitigation efforts.
  • Work in a fast-paced, high-growth environment with shifting priorities, evolving technical requirements, and a diverse portfolio of concurrent projects.
Desired Qualifications
  • Ability to interpret engineering drawings, CAD models, technical specifications, and design documentation across mechanical and electrical systems.

Element Biosciences makes DNA sequencing with the AVITI System, a compact benchtop NGS platform that pairs high accuracy with low run costs. The system delivers sequencing data at about $1 per million reads and can be integrated into workflows through partnerships with companies like QIAGEN for end-to-end solutions. The company stands out by offering affordable, high-quality sequencing and by supporting researchers with programs such as the AVITI for All Grant that provides free sequencing. Its goal is to broaden access to sequencing, enabling more projects within typical budgets across academic and commercial settings.

Company Size

201-500

Company Stage

Series E

Total Funding

$853M

Headquarters

San Diego, California

Founded

2017

Get referred to Element Biosciences

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Samsung invested $175 million on June 9, 2026, becoming Element's largest shareholder.
  • VITARI launched February 19, 2026, with $100 genomes and pre-orders already booked.
  • ISO 13485 certification on June 17, 2026 opens AVITI Dx and tissue profiling.

What critics are saying

  • 10x sued Element on May 8, 2026; AVITI24 faces damages and injunction.
  • Illumina is appealing Munich and fighting Delaware plus antitrust cases simultaneously.
  • Failed diagnostics launches or patent losses could choke revenue before H2 2026 shipments.

What makes Element Biosciences unique

  • AVITI and VITARI combine high accuracy, modular workflows, and lower sequencing costs.
  • Element bundles genomics, multiomics, and partner software into one open platform.
  • Munich court affirmed Element sequencing IP against Illumina on July 14, 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

100% company-paid medical, dental, & vision coverage

Flexible spending & health savings accounts

Premier mental health care

401(k) with immediately vested 4% company match

Company-paid Life and AD&D insurance

Stock option grants

Flexible time off

10 paid annual holidays

8-weeks paid parental leave

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
비즈워치
Jun 10th, 2026
Samsung bets $200M on DNA sequencing firm Element Biosciences to boost Galaxy Health ecosystem

Samsung Electronics has invested $175 million (approximately ₩270 billion) in US genetic analysis equipment company Element Biosciences, becoming its largest shareholder. This marks Samsung's second funding round in Element, following its Series D participation last year. Founded in 2017, Element specialises in DNA sequencing technology with 99.99% accuracy at reduced costs. Its multiomics platform analyses DNA, RNA, proteins and cellular changes through a single system, a capability particularly valuable for disease diagnosis and drug discovery. Samsung plans to integrate Element's genomic analysis technology with data from its Galaxy Health ecosystem, including Galaxy Watch and Galaxy Ring devices, to develop personalised healthcare services powered by AI. The investment aligns with Samsung's broader MedTech strategy, following previous acquisitions of companies like Samsung Medison and Sonio.

Yonhap Infomax
Jun 9th, 2026
Samsung Electronics becomes largest shareholder in US gene sequencing firm Element Biosciences with $175M investment

Samsung Electronics has become the largest shareholder in Element Biosciences, a US-based genetic sequencing equipment company, following a $175 million investment in the firm's Series E funding round. This follows Samsung's participation in Element's Series D round in July 2024. Founded in 2017 in San Diego, Element develops DNA sequencing technology with 99.99% genome analysis accuracy and low costs. The company launched its AVITI mid-sized sequencing device in 2022 and is preparing to introduce VITARI, which increases analysis capacity fivefold whilst reducing costs by over half. Samsung aims to secure core technologies in the precision medicine market and strengthen growth drivers in medical devices, digital health and AI. The investment will not result in management control changes at Element.

FinancialContent
Jun 9th, 2026
Element Biosciences raises $175M+ Series E from Samsung to expand genomic and multiomic research platforms

Element Biosciences has secured an upsized Series E financing round, including $175 million from Samsung Electronics and undisclosed amounts from other investors. The funding will accelerate commercialisation of the company's genomic and multiomic solutions and expand its global presence. The capital will support Element's product portfolio, including its AVITI sequencing platform, the recently announced VITARI high-throughput system, and upcoming launches of AVITI Dx and tissue profiling capabilities. Since launching AVITI in 2022, Element has expanded to serve customers in over 40 countries across academic, pharmaceutical and clinical research organisations. The financing, subject to regulatory approval, follows Element's $277 million Series D round announced in July 2024. The San Diego-based company develops platforms for genomic, transcriptomic, protein, spatial and cellular analyses.

Front Line Genomics
Mar 2nd, 2026
Week in Brief: Week Ending 27th February

Week in Brief: week ending 27th february. Lyndsey Fletcher 2 March 2026 What's been going on in the life sciences world this week? Check out Week in Brief for an overview of the biggest news from the last seven days. New announcements have taken the sequencing world by storm this week as several companies announced the launch of new products, and provided updates on their technology: * Element Biosciences announced the launch of the VITARI system, a high-throughput benchtop sequencer capable of sequencing a whole genome for $100. * Ultima Genomics launched the UG200 series, which features two configurations, UG200 and UG200 Ultra, designed to deliver up to 30,000 and 60,000 genomes a year respectively. * Illumina published an 18 month roadmap for the NovaSeq X platform, which aims to improve accuracy, throughput and turnaround time, and expand the applications of the platform. A study has found that many genetic variants that increase the risk of autoimmune hypothyroidism also tend to lower the risk of skin cancer. The findings suggest a shared genetic basis where heightened immune activity can protect against cancer but promote autoimmunity. Scientists have used a high-throughput method to test over 220,000 DNA variants and create detailed maps showing which specific genetic changes affect gene activity in different cell types. The work has clarified how variants influence traits like blood pressure, cholesterol, and blood sugar, helping to narrow down actionable mutations. A phase I clinical trial for a prostate cancer treatment has shown that a 'cloaking device' helped to keep an immunotherapy drug hidden and inactive until it reached tumour cells. This mechanism meant that side effects were minimised, and nearly half of the patients involved in the trial saw tumour shrinkage. In another prostate cancer drug trial, a novel targeted radiotherapy injection delivered radioactive therapy directly to cancer cells, shrinking or halting growth of tumours in over 80% of participants. The drug uses a 'homing device' to identify a specific antigen on the surface of the tumour cells. A new study has found that exposure to cigarette smoke causes epigenetic changes in key retinal cells, accelerating aging. These findings explain why smokers are more likely to develop age-related macular degeneration, a leading cause of blindness. Researchers have discovered that getting 'chills' or tingles when listening to music or engaging with art or literature is partly heritable. Some of the genes linked to this response were associated with other personality traits, and some had an impact across music, poetry and visual arts. A new study has found that 'jumping' segments of human DNA known as genetic parasites can destabilise the genome early in tumour development, creating mutations that fuel cancer evolution. These mobile DNA elements may play a critical role in the initial stages of cancer formation by promoting genomic instability. Scientists have discovered that high-dose vitamin B3 supplements dramatically extended survival and reversed symptoms in a mouse model of NAXD deficiency, a fatal childhood genetic disorder. This approach also identified other genetic conditions that might respond to B-vitamin therapy. Check out last week's Week in Brief here. Share via:

Business Wire
Feb 23rd, 2026
biomodal and Element Biosciences unite multiomic solutions with AVITI sequencing systems to accelerate clinical research

Biomodal, an omics-based life sciences technology company, has announced that its duet multiomic solutions are now compatible with Element Biosciences' AVITI24 5D multiomics and AVITI sequencing instruments. The integration, validated at the University of Minnesota Genomics Center, aims to enhance sensitivity for cancer, ageing and neurodegenerative disease research. The collaboration combines biomodal's 5-base and 6-base sequencing solutions with Element's sequencing systems, enabling complete methylation detection and delivering actionable insights within a single streamlined process. AVITI users gain access to biomodal's software pipeline, creating an end-to-end workflow for next-generation sequencing. Biomodal's platform-agnostic technology integrates pre-sequencing workflow with post-sequencing informatics to generate genetic and epigenetic data from a single sample in one run.